TRENDING STOCKS (30 min)

RECENT INFLUENTIAL RESEARCHERS

Add stocks to your Research List. Once added, this section will show the next upcoming user-posted catalysts. This feature allows you to quickly review the most pertinent information. Such data can significantly trigger stock movement and determine its potential.
or

lafrentzjordan7904/16/2018MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, F

6.

tgaller6502/01/2018Today is another example.

7.

tgaller6502/07/2018Made my profit

8.

lafrentzjordan7902/07/2018Hate to share this news: - Prices 4,419,890 share common stock offering at $9.05 per share